Invitation to Sora Park, Chairperson of the Regenerative Medicine Promotion Foundation
[Asia Economy Honam Reporting Headquarters Reporter Yoon Jamin] Jeonnam National University Hospital (Director Ahn Young-geun) recently hosted a seminar titled "Advanced Regenerative Bio Act and Directions for Regenerative Medicine Development" by inviting Park Sora, Chairperson of the Regenerative Medicine Promotion Foundation, the hospital announced on the 6th.
The event was attended by Director Ahn Young-geun, Director Kim Jaemin of the Biomedical Research Institute, Director Lee Seongsu of the Regenerative Medicine Research Center, as well as researchers interested in regenerative medicine clinical research, and related officials from local governments and institutions.
Regenerative medicine refers to medical technology that replaces or regenerates damaged human cells, tissues, or organs to restore normal function or create new ones.
It is a convergent treatment technology enabling personalized medicine, the fundamental cure for diseases, and is divided into cell therapy, gene therapy, and tissue engineering therapy.
Recently, Novartis’s cancer drug "Kymriah," covered by health insurance, is classified as an advanced regenerative bio-pharmaceutical developed through advanced regenerative medicine clinical research. "Kymriah" is a personalized cancer drug that combines the characteristics of cell, gene, and immune therapies.
At this seminar, Chairperson Park presented the latest global trends in advanced regenerative medicine and suggested directions for commercialization.
Chairperson Park said, "The market growth for cell-based gene therapies among regenerative medicine treatments is expected to be very strong," adding, "Many domestic companies are actively investing in the cell and gene therapy fields, including acquiring overseas CDMO companies."
She also stated, "To enable more patients to use expensive advanced bio-pharmaceuticals, in addition to health insurance reimbursement, technologies to reduce production costs, manufacturing infrastructure, and hospital-company collaboration are necessary."
Director Ahn Young-geun said, "Currently, countries including South Korea, the United States, Europe, and Japan are actively conducting research and commercialization related to regenerative medicine, including cell therapies," and added, "I hope this seminar will broaden understanding of regenerative medicine and create opportunities to establish a new medical paradigm."
Meanwhile, Jeonnam National University Hospital was designated as an advanced regenerative medicine institution by the Ministry of Health and Welfare in February this year, and translational research using stem cells for cardiovascular diseases, stem cells for chronic otitis media treatment, and oral tissue regeneration scaffolds is actively underway. In South Korea, a total of 12 advanced regenerative medicine clinical studies are being conducted as of June this year.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
